Syneos Health, Inc. - (SYNH): Price and Financial Metrics
SYNH Price/Volume Stats
| Current price | $41.74 | 52-week high | $79.77 |
| Prev. close | $41.75 | 52-week low | $22.89 |
| Day low | $41.62 | Volume | 651,182 |
| Day high | $41.78 | Avg. volume | 2,250,339 |
| 50-day MA | $39.70 | Dividend yield | N/A |
| 200-day MA | $40.88 | Market Cap | 4.33B |
SYNH Stock Price Chart Interactive Chart >
SYNH POWR Grades
- Value is the dimension where SYNH ranks best; there it ranks ahead of 89.37% of US stocks.
- The strongest trend for SYNH is in Growth, which has been heading down over the past 167 days.
- SYNH's current lowest rank is in the Momentum metric (where it is better than 4.91% of US stocks).
SYNH Stock Summary
- With a price/earnings ratio of 29.16, SYNEOS HEALTH INC P/E ratio is greater than that of about 76.12% of stocks in our set with positive earnings.
- With a year-over-year growth in debt of -10.2%, SYNEOS HEALTH INC's debt growth rate surpasses 25.32% of about US stocks.
- SYNEOS HEALTH INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 6.63%, greater than the shareholder yield of 76.28% of stocks in our set.
- Stocks that are quantitatively similar to SYNH, based on their financial statements, market capitalization, and price volatility, are H, GPRE, DY, CHUY, and TTEC.
- Visit SYNH's SEC page to see the company's official filings. To visit the company's web site, go to www.syneoshealth.com.
SYNH Valuation Summary
- In comparison to the median Healthcare stock, SYNH's EV/EBIT ratio is 111.67% higher, now standing at 25.4.
- SYNH's price/earnings ratio has moved up 58.5 over the prior 104 months.
Below are key valuation metrics over time for SYNH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SYNH | 2023-05-23 | 0.8 | 1.3 | 29.2 | 25.4 |
| SYNH | 2023-05-22 | 0.8 | 1.3 | 29.2 | 25.4 |
| SYNH | 2023-05-19 | 0.8 | 1.2 | 29.1 | 25.4 |
| SYNH | 2023-05-18 | 0.8 | 1.2 | 29.0 | 25.3 |
| SYNH | 2023-05-17 | 0.8 | 1.2 | 29.1 | 25.3 |
| SYNH | 2023-05-16 | 0.8 | 1.2 | 29.1 | 25.4 |
SYNH Growth Metrics
- Its 2 year revenue growth rate is now at 13.14%.
- Its 5 year net income to common stockholders growth rate is now at 67.37%.
- Its year over year net income to common stockholders growth rate is now at 22.4%.
The table below shows SYNH's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 5,393.082 | 426.981 | 266.497 |
| 2022-09-30 | 5,406.599 | 489.143 | 286.928 |
| 2022-06-30 | 5,418.606 | 405.272 | 278.122 |
| 2022-03-31 | 5,340.478 | 394.077 | 242.283 |
| 2021-12-31 | 5,212.97 | 450.278 | 234.831 |
| 2021-09-30 | 4,979.605 | 378.625 | 250.758 |
SYNH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SYNH has a Quality Grade of D, ranking ahead of 21.57% of graded US stocks.
- SYNH's asset turnover comes in at 0.618 -- ranking 262nd of 563 Business Services stocks.
- INS, HURN, and MEDP are the stocks whose asset turnover ratios are most correlated with SYNH.
The table below shows SYNH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.618 | 0.233 | 0.100 |
| 2021-06-30 | 0.602 | 0.238 | 0.096 |
| 2021-03-31 | 0.579 | 0.234 | 0.085 |
| 2020-12-31 | 0.580 | 0.230 | 0.083 |
| 2020-09-30 | 0.602 | 0.225 | 0.067 |
| 2020-06-30 | 0.612 | 0.218 | 0.070 |
SYNH Price Target
For more insight on analysts targets of SYNH, see our SYNH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $80.92 | Average Broker Recommendation | 1.33 (Strong Buy) |
Syneos Health, Inc. - (SYNH) Company Bio
Syneos Health, formerly INC Research Holdings, provide the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company was founded in 2010 and is based in Raleigh, North Carolina.
Latest SYNH News From Around the Web
Below are the latest news stories about SYNEOS HEALTH INC that investors may wish to consider to help them evaluate SYNH as an investment opportunity.
Syneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health EquityNewly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across OrganizationMORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Batisha Anson to the newly created role of Global Head of Patient Diversity and Health Equity. In this role, Anson will advance Syneos Health’s goal to improve diverse representation of pati |
Syneos Health Leaders Recognized by HBAHealthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry ImpactMORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer Sozio, SVP Clinical Operations, FSP360, and Caitlin Purinai, Senior Director, Human Resources Business Partner, have been recognized by the Healthcare Businesswomen’s Association (HBA) as admirable female |
Syneos Health Leaders Recognized as PM360 2023 ELITE Award RecipientsCompany Executives Honored for Notable Biopharmaceutical Industry ImpactMORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual |
Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger PlanSyneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium. |
Syneos Health (SYNH) Announces a $7.1 Billion Merger AgreementSyneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium. |
SYNH Price Returns
| 1-mo | 8.56% |
| 3-mo | 18.48% |
| 6-mo | 21.48% |
| 1-year | -43.23% |
| 3-year | -28.17% |
| 5-year | -2.48% |
| YTD | 13.79% |
| 2022 | -64.28% |
| 2021 | 50.71% |
| 2020 | 14.55% |
| 2019 | 51.14% |
| 2018 | -9.75% |
Continue Researching SYNH
Want to see what other sources are saying about Syneos Health Inc's financials and stock price? Try the links below:Syneos Health Inc (SYNH) Stock Price | Nasdaq
Syneos Health Inc (SYNH) Stock Quote, History and News - Yahoo Finance
Syneos Health Inc (SYNH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...